Narcolepsy patients told FDA and companies at the agency's latest patient-focused drug development meeting they want a better balance of alertness and sleep. Specifically, this means better resolution of excessive daytime sleepiness - their worst symptom - and reductions in the sleep disruption side effects associated with current drugs.

It remains to be seen whether anything in the narcolepsy pipeline can achieve that balance.